आदित्य रघुनाथ द्वाराInvesting.com -- कोरोनावायरस की दूसरी लहर उत्परिवर्तित होती रहती है और इसके दुष्परिणाम उतने ही बुरे होते हैं जितने कि बीमारी। जबकि संक्रमण की संख्या में लगातार...
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
|---|---|---|---|---|---|
| मूविंग एवरेज | बेचना | बेचना | बेचना | मजबूत विक्रय | खरीदें |
| तकनीकी संकेतक | बेचना | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय | खरीदें |
| सारांश | बेचना | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय | खरीदें |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 1,625.10 | 1,635.50 | 1,608.00 | +23.55 | +1.47% | 8.21M | NSE | |||
| 54.45 | 56.40 | 54.05 | -1.35 | -2.42% | 4.07M | NSE | |||
| 1,124.20 | 1,134.00 | 1,061.00 | +52.45 | +4.89% | 2.00M | NSE | |||
| 420.00 | 427.90 | 411.80 | +9.55 | +2.33% | 32.57M | NSE | |||
| 121.00 | 124.35 | 120.20 | -1.75 | -1.43% | 531.54K | NSE | |||
| 8.96 | 9.36 | 8.51 | +0.45 | +5.29% | 4.42K | BSE | |||
| 81,737.35 | 82,000.00 | 79,144.65 | +2,280.85 | +2.87% | 20.89K | NSE | |||
| 125.90 | 128.80 | 125.00 | -1.15 | -0.91% | 7.37K | NSE | |||
| 6.45 | 6.45 | 6.15 | 0.00 | 0.00% | 0.00 | NSE | |||
| 59.00 | 59.00 | 59.00 | +2.70 | +4.80% | 1.20K | NSE | |||
| 37.45 | 37.80 | 36.15 | +0.40 | +1.08% | 9.29K | BSE | |||
| 1,149.05 | 1,166.15 | 1,141.20 | -5.75 | -0.50% | 40.00K | NSE | |||
| 358.15 | 361.85 | 352.65 | -2.00 | -0.56% | 4.10M | NSE | |||
| 174.55 | 176.25 | 173.95 | +0.60 | +0.34% | 1.07M | NSE | |||
| 3,839.00 | 3,904.00 | 3,802.90 | -32.30 | -0.83% | 1.67M | NSE |
NATCO Pharma Limited, a pharmaceutical company, develops, manufactures, and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, ovary, etc.; and APIs in various categories, such as oncology, central nervous system, pain management, and CV care. The company also offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina and CHF. The company markets its products in approximately 40 countries, including India, the United States, and internationally. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.